Coronavirus

Microbiology Testing/Clinical Microbiology Market size worth $ 10.11 Billion, Globally, by 2028 at 10.17% CAGR: Verified Market Research®

Retrieved on: 
Monday, April 11, 2022
Market research, Company, CAGR, DST, USD, World Health Organization, Agilent Technologies, Diagnosis, Microbiology, Coronavirus, Mortality, Research, Epidemic, World, Incidence, Midsayap Diagnostic Center and Hospital, Prevalence, Roche, Abbott, Department of Science and Technology, Diarrhea, Government, Health, COVID-19, Becton, Dickinson and Company headquarters, Thermo Fisher Scientific, Geography, Urinary tract infection, Solution, Department, Tuberculosis, Degenerative disease, Bloodstream infections, Hospital, Infection, Pharmaceutical industry, Medical device, Bruker, Technology

JERSEY CITY, N.J., April 11, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Microbiology Testing/Clinical Microbiology Market" By Product (Instruments, Reagents), By Disease Area (Respiratory Diseases, Bloodstream Infections), By Application (Pharmaceutical Applications, Energy Applications), By End User (Hospitals and Diagnostic Centers, Academic and Research Institutes), and By Geography. According to Verified Market Research, the Global Microbiology Testing/Clinical Microbiology Market size was valued at USD 4.66 Billion in 2020 and is projected to reach USD 10.11 Billion by 2028, growing at a CAGR of 10.17% from 2021 to 2028.

Key Points: 
  • Technological developments in disease diagnostics, growing incidence of infectious diseases, increased public-private investments & funding, and rise in outbreaks of epidemics have been driving the Microbiology Testing/Clinical Microbiology Market.
  • According to Verified Market Research, the Global Microbiology Testing/Clinical Microbiology Market size was valued at USD 4.66 Billion in 2020 and is projected to reach USD 10.11 Billion by 2028, growing at a CAGR of 10.17% from 2021 to 2028.
  • As a result of the rising prevalence and incidence of infectious diseases, the demand for microbiological testing is increasing, leading to global market growth.
  • Verified Market Research has segmented the Global Microbiology Testing/Clinical Microbiology Market On the basis of Product, Disease Area, Application, End User, and Geography.

Microbiology Testing/Clinical Microbiology Market size worth $ 10.11 Billion, Globally, by 2028 at 10.17% CAGR: Verified Market Research®

Retrieved on: 
Monday, April 11, 2022
Market research, Company, CAGR, DST, USD, World Health Organization, Agilent Technologies, Diagnosis, Microbiology, Coronavirus, Mortality, Research, Epidemic, World, Incidence, Midsayap Diagnostic Center and Hospital, Prevalence, Roche, Abbott, Department of Science and Technology, Diarrhea, Government, Health, COVID-19, Becton, Dickinson and Company headquarters, Thermo Fisher Scientific, Geography, Urinary tract infection, Solution, Department, Tuberculosis, Degenerative disease, Bloodstream infections, Hospital, Infection, Pharmaceutical industry, Medical device, Bruker, Technology

JERSEY CITY, N.J., April 11, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Microbiology Testing/Clinical Microbiology Market" By Product (Instruments, Reagents), By Disease Area (Respiratory Diseases, Bloodstream Infections), By Application (Pharmaceutical Applications, Energy Applications), By End User (Hospitals and Diagnostic Centers, Academic and Research Institutes), and By Geography. According to Verified Market Research, the Global Microbiology Testing/Clinical Microbiology Market size was valued at USD 4.66 Billion in 2020 and is projected to reach USD 10.11 Billion by 2028, growing at a CAGR of 10.17% from 2021 to 2028.

Key Points: 
  • Technological developments in disease diagnostics, growing incidence of infectious diseases, increased public-private investments & funding, and rise in outbreaks of epidemics have been driving the Microbiology Testing/Clinical Microbiology Market.
  • According to Verified Market Research, the Global Microbiology Testing/Clinical Microbiology Market size was valued at USD 4.66 Billion in 2020 and is projected to reach USD 10.11 Billion by 2028, growing at a CAGR of 10.17% from 2021 to 2028.
  • As a result of the rising prevalence and incidence of infectious diseases, the demand for microbiological testing is increasing, leading to global market growth.
  • Verified Market Research has segmented the Global Microbiology Testing/Clinical Microbiology Market On the basis of Product, Disease Area, Application, End User, and Geography.

SAMSARA LUGGAGE LAUNCHES THE TAG SMART COLLECTION COMBINED WITH APPLE AIRTAG

Retrieved on: 
Monday, April 11, 2022
Company, Private Securities Litigation Reform Act, Away (company), NEW, AirTag, SAML, Coronavirus, Multimedia, Apple, SEC, Find My, Rapid City, Black Hills and Western Railroad, Silver, Internet of things, Atmosphere, CEO, U.S. Securities and Exchange Commission, IPhone, NFT, Security (finance), Travel, Technology, Industry, Collection, IOT, Samsara (2011 film), OTCQB, Desperate, TSA, Annual report, Instagram, Mobile phone, Baggage, Saṃsāra

NEW YORK, April 11, 2022 /PRNewswire/ -- Samsara Luggage (OTCQB: SAML), maker of innovative travel products, meets travelers in the Apple ecosystem with the launch of the Tag Smart Collection by Samsara. Tag Smart combines with the Apple AirTag so travelers can now track their suitcase using the Find My app on their iPhone. Using a Bluetooth signal, the iPhone maps your Samsara location with precision and ease for a more effortless travel experience. The Tag Smart Device is included in the suitcase and designed to deliver on functionality and technology that is easy to navigate. Tag Smart is specially made for the AirTag with an interior compartment that secures the device from the inside. The suitcase's aluminum frame and TSA-approved combination locks keep the AirTag protected from any outside tampering. Samsara gave its iconic design an upgrade with the 23" Carry-on Grand, the maximum size allowed for US domestic travelers.

Key Points: 
  • NEW YORK, April 11, 2022 /PRNewswire/ -- Samsara Luggage (OTCQB: SAML), maker of innovative travel products, meets travelers in the Apple ecosystem with the launch of the Tag Smart Collection by Samsara.
  • Tag Smart combines with the Apple AirTag so travelers can now track their suitcase using the Find My app on their iPhone.
  • Samsara welcomes the new collection with a brand campaign that will get the digital world hyped for Tag Smart.
  • Samsara Luggage, Inc. ("Samsara," "Samsara Luggage" or the "Company") (OTCQB: SAML) is a global smart luggage and smart travel brand with a deep belief in creating a world where travel isn't a hassle, but rather an effortless experience.

Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-KIT, Proves Effective Against Aggressive Cancer Cells

Retrieved on: 
Monday, April 11, 2022
Private Securities Litigation Reform Act, Therapy, Cancer, Organization, Acute myeloid leukemia, NASDAQ, Anaphylaxis, NEW, Patent, Cell death, Mastocytosis, KIT, Alzheimer's disease, B cell, Survival, Risk, Disease, North Carolina State University, NME, Mast cell leukemia, Assistant, Atopic dermatitis, Quality of life, HT, U.S. Securities and Exchange Commission, RNA transfection, Wuxi, Annual report, FDA, Mast cell sarcoma, Stromal cell, Patient, IP, Vaccine, Pharmaceutical industry, Hoth, Coronavirus

NEW YORK, April 11, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced a development updates for its novel cancer therapeutic, HT-KIT.

Key Points: 
  • NEW YORK, April 11, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced a development updates for its novel cancer therapeutic, HT-KIT.
  • Based on the initial proof-of-concept success, Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggressive cancer with poor prognosis.
  • Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.
  • Although Hoth believes that the expectations reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such outcomes.

Embedded Lending Market in Asia Pacific - Business and Investment Opportunities: A US $99,842.6 Million Market by 2029 with CAGR of 26% Forecast During 2022-2029

Retrieved on: 
Monday, April 11, 2022
CAGR, Sale, Atomè, Investment, Pine Labs, Coronavirus, MCO, Local Investing Opportunity Network, Financial technology, Industry, Fintech Valley Vizag, Table, Partnership, Semiconductor, Bank, Online shopping

DUBLIN, April 11, 2022 /PRNewswire/ --The "Asia Pacific Embedded Lending Business and Investment Opportunities - Q1 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 11, 2022 /PRNewswire/ --The "Asia Pacific Embedded Lending Business and Investment Opportunities - Q1 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • The embedded lending industry is expected to grow steadily over the forecast period, recording a CAGR of 26.2% during 2022-2029.
  • The embedded lending revenues in the region will increase from US$27,284.1 million in 2022 to reach US$99,842.6 million by 2029.
  • The Asia Pacific is home to the leading embedded lending providers in the world.

Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models

Retrieved on: 
Friday, April 8, 2022
Private Securities Litigation Reform Act, PDX, Cancer, BRCA1, Therapy, PARP, Parpi, DNA, Drug resistance, Marketing, Risk, Forward-looking statement, Homologous recombination, Coronavirus, Patient, PLK1, KRAS, Survival, AACR, Ernest, SOC, American Association, Precision medicine, Failure, U.S. Securities and Exchange Commission, Poster, DNA repair, Ovarian cancer, Government, Association, American Association for Cancer Research, Safety, Technology, Annual general meeting, Nasdaq, COVID-19, CRDF, SAN, Maintenance, FDA, Data, Reversal, Security (finance), Pharmaceutical industry

SAN DIEGO, April 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the results of preclinical studies evaluating the anti-cancer activity of onvansertib in combination with the PARP inhibitor (PARPi) olaparib in PARPi-resistant patient-derived xenograft (PDX) ovarian cancer models. The results are featured in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans, Louisiana from April 8-13, 2022.

Key Points: 
  • "We are very pleased with the results, which showed onvansertib and olaparib synergistically combining to generate strong activity against PARPi-resistant patient-derived ovarian cancer models.
  • Given the current lack of effective treatment options for patients showing PARPi resistance, we believe these data are supportive of evaluating this combination within a PARPi-resistant clinical setting."
  • Preclinical studies featured in the AACR poster evaluated onvansertib-olaparib combination treatment in three olaparib-resistant patient-derived xenograft (PDX) ovarian cancer models.
  • Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers.

Healthcare Technology Management Market worth $12.9 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, April 8, 2022
Adoption, GE Healthcare, CAGR, Dialysis, Coronavirus, 3D ultrasound, PET-CT, Hospital, CT, OEM, Government, Health, Technology, Optical disc image, COVID-19, Patient safety, ISO, Solution, MRI, Maintenance, ABM Industries, Patient, Medical device, Pharmaceutical industry, Sodexo, Endoscopy, Laser, Growth

The novel coronavirus pandemic has exerted enormous strain on the functioning of healthcare and life sciences industries.

Key Points: 
  • The novel coronavirus pandemic has exerted enormous strain on the functioning of healthcare and life sciences industries.
  • Based on the type of service, the healthcare technology management market is segmented into maintenance & repair, capital planning, integrated software platform, labor management, supply chain (procurement), cyber security, and quality & regulatory compliance.
  • The maintenance & repair segment accounted for the largest share of 36.14% of the US healthcare technology management market in 2020.
  • Based on facility types, the US healthcare technology management market is segmented into acute care, post-acute care, and non-acute care facilities.

Healthcare Technology Management Market worth $12.9 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, April 8, 2022
Adoption, GE Healthcare, CAGR, Dialysis, Coronavirus, 3D ultrasound, PET-CT, Hospital, CT, OEM, Government, Health, Technology, Optical disc image, COVID-19, Patient safety, ISO, Solution, MRI, Maintenance, ABM Industries, Patient, Medical device, Pharmaceutical industry, Sodexo, Endoscopy, Laser, Growth

The novel coronavirus pandemic has exerted enormous strain on the functioning of healthcare and life sciences industries.

Key Points: 
  • The novel coronavirus pandemic has exerted enormous strain on the functioning of healthcare and life sciences industries.
  • Based on the type of service, the healthcare technology management market is segmented into maintenance & repair, capital planning, integrated software platform, labor management, supply chain (procurement), cyber security, and quality & regulatory compliance.
  • The maintenance & repair segment accounted for the largest share of 36.14% of the US healthcare technology management market in 2020.
  • Based on facility types, the US healthcare technology management market is segmented into acute care, post-acute care, and non-acute care facilities.

Funding Deadline Extended to April 11 - Indoor Air Quality (IAQ) Funding Available for Private Schools Throughout California

Retrieved on: 
Friday, April 8, 2022
Building, Air quality index, Congress, California Department of Education, Consultant, NPS, Automotive Service Excellence, EANS, COVID-19, Pure Air, ARP, White, Microsoft Excel, Vendor, Atmosphere, Health, American Rescue Plan Act of 2021, School, White House, Atmosphere of Earth, Safety, Indoor air quality, IAQ, Coronavirus, Needs assessment, Student, Program, Infection, Solution, HEPA, CDE, PPE, OTC, Federation, Pacific Time Zone, Medicine, Online shopping, Part

CHARLESTON, S.C., April 8, 2022 /PRNewswire/ -- Eligible California Non-public Schools (NPS) have until April 11, 2022 at 5PM Pacific Time to apply for access to over $180 million made available through the American Rescue Plan (ARP) Emergency Assistance to Non-public Schools (EANS) Program which provided for over $5.5B to assist Non-Public Schools that can be utilized to supplement purchases designed to enhance health and safety in schools and classrooms such as Indoor Air Quality (IAQ). The federal government has previously allocated over $121B for our national K-12 Public Schools and in March 2022 the White House highlighted an additional $350B that is available to address improving Indoor Air Quality through its "Clean Air in Buildings Challenge".  Clean Indoor Air in schools, buildings, and the places we gather is essential and can no longer be ignored.

Key Points: 
  • - Emergency Funding for at least $180M available to California K-12 Non-Public Schools (NPS) through the American Rescue Plan (ARP) Emergency Assistance to Non-public Schools (EANS II) Program.
  • - BOX Pure Air is the predominant listed vendor in the Vendor Selection and Services - Federal Stimulus Funding (CA Dept of Education) for Portable Air Purification Systems.
  • Clean Indoor Air in schools, buildings, and the places we gather is essential and can no longer be ignored.
  • The company strives to provide the best products to help clean air through the deployment of high-efficiency air purification technologies.

American Council of Learned Societies Awards 24 Sustaining Public Engagement Grants

Retrieved on: 
Friday, April 8, 2022
Organization, Literature, Imprisonment, University, Public health, Coronavirus, American Rescue Plan Act of 2021, Humanities, National Endowment for the Humanities, Research, Color, Social, ACLS, Lists of disasters, Philosophy, Learning, Knowledge, Act, Time, American Council of Learned Societies, NEH, Solution, American Council, Awareness, Learned society, History, Medicine

NEW YORK, April 8, 2022 /PRNewswire-PRWeb/ -- The American Council of Learned Societies (ACLS) today announced the 2022 awardees for the Sustaining Public Engagement Grant Program, a $3.5 million responsive funding program made possible by a grant from the National Endowment for the Humanities (NEH) as part of the Sustaining the Humanities through the American Rescue Plan (SHARP) initiative.

Key Points: 
  • The 24 grantees represent outstanding public programs based at a variety of public and private institutions from 18 states and Puerto Rico.
  • Meet the 2022 Sustaining Public Engagement Grantees.
  • "The National Endowment for the Humanities is grateful to the American Council of Learned Societies for administering American Rescue Plan funding to speed economic recovery within the higher education sector," said NEH Chair Shelly C. Lowe (Navajo).
  • American Council of Learned Societies:
    Formed in 1919, the American Council of Learned Societies (ACLS) is a nonprofit federation of 78 scholarly organizations.